Tag: UCB

BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsUCB

River Pines Capital Announces Strategic Investment in Bendon, a Provider of Screen-Free Children’s Educational and Activity Products

AGIBOT Brings APC 2026 to Indonesia, Accelerating Local Deployment of Embodied AI

GENESIS AND GENESIS INSPIRATION FOUNDATION PROMOTE STEAM LEARNING IN CHICAGO

Tag: UCB

BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us